Metatarsal stress fractures in patients with multiple myeloma treated with long-term bisphosphonates: A report of six cases

Journal of Bone and Joint Surgery

Volumn 93, Issue 18, 2011, Pages

  Waterman, Gabriel N ^a   Yellin, Ori ^b   Jamshidinia, Kamran ^c   Swift, Regina A ^a   Tamkin, James A ^a   Audell, Robert A ^a   Berenson, James R ^d  

^a Oncotherapeutics ^*  (United States)

^b Oncotherapeutic   (United States)

^c Kaiser South Sacramento   (United States)

^d INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CLARITHROMYCIN; DEXAMETHASONE; DOXORUBICIN; GLUCOCORTICOID; IMMUNOGLOBULIN A; LENALIDOMIDE; MELPHALAN; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PREDNISONE; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURGERY; CASE REPORT; CERVICAL SPINE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FOOT PAIN; FRACTURE NONUNION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; JAW OSTEONECROSIS; LEG SWELLING; MAINTENANCE THERAPY; MALE; METATARSAL BONE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOTICS; OSTEOID; PARESTHESIA; PATHOLOGIC FRACTURE; PERIPHERAL NEUROPATHY; PLASMACYTOMA; PRIORITY JOURNAL; RIB FRACTURE; SPINE FUSION; STEM CELL TRANSPLANTATION; STRESS FRACTURE; VERTEBRA FRACTURE; WALKING; WALKING AID;

EID: 80053187686     PISSN: 00219355     EISSN: 15351386     Source Type: Journal    
DOI: 10.2106/JBJS.J.00455     Document Type: Article

References (72)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96. (Pubitemid 351521864)
2. Smith, ML, Newland AC. Treatment of myeloma. QJM. 1999;92:11-4. (Pubitemid 29034095)
3. Musto P. The role of bisphosphonates for the treatment of bone disease in multiple myeloma. Leuk Lymphoma. 1998;31:453-62. (Pubitemid 29050587)
4. Kastrinakis NG, Gorgoulis VG, Foukas PG, Dimopoulos MA, Kittas C. Molecular aspects of multiple myeloma. Ann Oncol. 2000;11:1217-28.
5. Berenson JR, Yellin O, Patel R, Duvivier H, Nassir Y, Mapes R, Abaya CD, Swift RA. A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res. 2009;15:1069-75.
6. Currey JD. Effects of differences in mineralization on the mechanical properties of bone. Phil Trans R Soc London B Biol Sci. 1984;304:509-18.
7. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13:581-9. (Pubitemid 28163009)
8. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-41. (Pubitemid 26411651)
9. Kanis JA, McCloskey EV. Bisphosphonates in multiple myeloma. Cancer. 2000; 88(12 Suppl):3022-32. (Pubitemid 30413186)
10. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996;334:488-93. (Pubitemid 26067736)
11. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998;16:593-602. (Pubitemid 28135605)
12. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7:377-87. (Pubitemid 33759002)
13. Roux C, Dougados M. Treatment of patients with Paget's disease of bone. Drugs. 1999;58:823-30.
14. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002;359: 2018-26. (Pubitemid 34663722)
15. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165-76. (Pubitemid 32452017)
16. Berenson JR. Biology and management of multiple myeloma. Totowa, NJ: Humana Press; 2004. Myeloma bone disease; p 251-71.
17. Santini D, Vespasiani Gentilucci U, Vincenzi B, Picardi A, Vasaturo F, La Cesa A, Onori N, Scarpa S, Tonini G. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol. 2003;14:1468-76. (Pubitemid 37304600)
18. Berenson J, Shirina N, Chen YM, Dimopoulos M. Survival in patients with multiple myeloma receiving zoledronic acid: stratification by baseline bone alkaline phosphatase levels. J Clin Oncol (Meeting Abstracts). 2006;24(18 Suppl): 7505.
19. Berenson JR, Yellin O, Crowley J, Makary A, Gravenor DS, Yang HH, Upadhyaya GH, Flinn IW, Staszewski H, Tiffany NM, Sanani S, Farber CM, Morganstein Duvivier H, Nassir Y, Sefaradi A, Shamouelian A, Swift RA. Overall survival among patients with multiple myeloma (MM) treated with zoledronic acid (ZOL) [abstract]. XII International Myeloma Workshop abstract book. February 26-March 1, 2009. Washington, DC, USA. Clin Lymphoma Myeloma. 2009;9 Suppl 1:S12-3.
20. Morgan G, Davies F, Gregory W, Bell SE, Szubert A, Navarro Coy N, Drayson M, Owen RG, Jackson GH, Child JA. Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): results of the Medical Research Council (MRC)Myeloma IX study. J Clin Oncol (Meeting Abstracts). 2010;28(15 Suppl):8021.
21. Marx RE, Stern DS. Oral and maxillofacial pathology: a rationale for diagnosis and treatment. Chicago: Quintessence Publishing; 2002. Biopsy principles and techniques; p 36-8.
22. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23:8380-7.
23. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, Bamia C, Terpos E, Tsionos K, Bamias A. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006;91: 968-71. (Pubitemid 44023154)
24. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294-301. (Pubitemid 40463979)
25. Schneider JP. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics. 2006; 61:31-3. (Pubitemid 43134037)
26. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008;39:224-31.
27. Armamento-Villareal R, Napoli N, Panwar V, Novack D. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med. 2006; 355:2048-50. (Pubitemid 44708036)
28. Imai K, Yamamoto S, Anamizu Y, Horiuchi T. Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy. J Bone Miner Metab. 2007;25:333-6. (Pubitemid 47283272)
29. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008; 22:346-50. (Pubitemid 351630250)
30. Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, Van der Meulen MC, Lorich DG, Lane JM. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int. 2009; 20:1353-62.
31. Wernecke G, Namduri S, DiCarlo EF, Schneider R, Lane J. Case report of spontaneous, nonspinal fractures in a multiple myeloma patient on long-term pamidronate and zoledronic acid. HSS J. 2008;4:123-7.
32. Grasko JM, Hermann RP, Vasikaran SD. Recurrent low-energy femoral shaft fractures and osteonecrosis of the jaw in a case of multiple myeloma treated with bisphosphonates. J Oral Maxillofac Surg. 2009;67:645-9.
33. US Food and Drug Administration. FDA drug safety communication: safety update for osteoporosis drugs, bisphosphonates, and atypical fractures. 2010 Oct 13. http://www.fda.gov/Drugs/DrugSafety/ucm229009.htm#safety. Accessed 2010 Nov 17.
34. Maitra RS, Johnson DL. Stress fractures. Clinical history and physical examination. Clin Sports Med. 1997;16:259-74. (Pubitemid 27190631)
35. Sanderlin BW, Raspa RF. Common stress fractures. Am Fam Physician. 2003; 68:1527-32. (Pubitemid 37296047)
36. Arndt A, Ekenman I, Westblad P, Lundberg A. Effects of fatigue and load variation on metatarsal deformation measured in vivo during barefoot walking. J Biomech. 2002;35:621-8. (Pubitemid 34292507)
37. Uthgenannt BA, Kramer MH, Hwu JA, Wopenka B, Silva MJ. Skeletal self-repair: stress fracture healing by rapid formation and densification of woven bone. J Bone Miner Res. 2007;22:1548-56. (Pubitemid 351229325)
38. Smrcina CM. Stress fractures in athletes. Nurs Clin North Am. 1991;26: 159-66.
39. Hockenbury RT. Forefoot problems in athletes. Med Sci Sports Exerc. 1999; 31(7 suppl):S448-58. (Pubitemid 29316180)
40. Pagliano J, Jackson D. The ultimate study of running injuries. Runner's World. 1980;15:42-50.
41. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-20.
42. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842-54.
43. Zogby RG, Baker BE. A review of nonoperative treatment of Jones' fracture. Am J Sports Med. 1987;15:304-7. (Pubitemid 17118957)
44. Ott SM. Fractures after long-term alendronate therapy. J Clin Endocrinol Metab. 2001;86:1835-6.
45. Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab. 2005; 90:1897-9.
46. Weinstein RS. True strength. J Bone Miner Res. 2000;15:621-5. (Pubitemid 30174015)
47. Melton LJ 3rd, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res. 2005;20: 487-93. (Pubitemid 40293498)
48. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006;81: 1047-53. (Pubitemid 44175016)
49. Ray NF, Chan JK, Thamer M, Melton LJ 3rd. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12:24-35. (Pubitemid 27053608)
50. McCloskey EV, Guest JF, Kanis JA. The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma. Drugs. 2001;61:1253-74. (Pubitemid 32744407)
51. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753-61. (Pubitemid 46780635)
52. Haddad FS, Mohanna PN, Goddard NJ. Bilateral femoral neck stress fractures following steroid treatment. Injury. 1997;28:671-3. (Pubitemid 28185120)
53. Berenson JR. New advances in the biology and treatment of myeloma bone disease. Semin Hematol. 2001;38(2 Suppl 3):15-20. (Pubitemid 32327950)
54. Russell RG, Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Croucher PI, Shipman C, Fleisch HA. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res. 1999;14 Suppl 2:53-65. (Pubitemid 29455800)
55. Rogers MJ, Watts DJ, Russell RG. Overview of bisphosphonates. Cancer. 1997; 80(8 Suppl):1652-60. (Pubitemid 27444037)
56. Mashiba T, Mori S, Burr DB, Komatsubara S, Cao Y, Manabe T, Norimatsu H. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab. 2005;23 Suppl:36-42.
57. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. 2001;28:524-31. (Pubitemid 32416465)
58. Berenson J, Cook R, Lipton A, Coleman R, Terpos E. Increased levels of urinary N-telopeptide of type I collagen correlate with reduced survival in patients with advanced multiple myeloma. Blood (ASH Annual Meeting Abstracts). 2007; 110:1499.
59. Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M, Facon T, Granena A, Gore M, Gratwohl A, Löwenberg B, Nikoskelainen J, Reiffers JJ, Samson D, Verdonck L, Volin L, and for the European Group for Bone Marrow Transplantation. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med. 1991;325: 1267-73.
60. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78: 21-33. (Pubitemid 36033957)
61. Kyle RA. Prognostic factors in multiple myeloma. Hematol Oncol. 1988;6: 125-30.
62. Grignani G, Gobbi PG, Formisano R, Pieresca C, Ucci G, Brugnatelli S, Riccardi A, Ascari E. A prognostic index for multiple myeloma. Br J Cancer. 1996;73: 1101-7. (Pubitemid 26131232)
63. O'Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V, Naresh K, Lampert I, Samson D, Narat S, Kanfer E, Olavarria E, Apperley JF, Rahemtulla A. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant. 2006;37:731-7.
64. Brenner H, Gondos A, Pulte D. Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica. 2009;94: 270-5.
65. Shima Y, Engebretsen L, Iwasa J, Kitaoka K, Tomita K. Use of bisphosphonates for the treatment of stress fractures in athletes. Knee Surg Sports Traumatol Arthrosc. 2009;17:542-50.
66. Ekenman I. Do not use bisphosphonates without scientific evidence, neither in treatment nor prophylactic, in the treatment of stress fractures. Knee Surg Sports Traumatol Arthrosc. 2009;17:433-4.
67. Mashiba T, Mori S. [Bone fracture and the healing mechanisms. The effects of anti-resorptive agents on fracture healing]. Clin Calcium. 2009;19:673-9. Japanese.
68. Li J, Mori S, Kaji Y, Mashiba T, Kawanishi J, Norimatsu H. Effect of bisphosphonate (incadronate) on fracture healing of long bones in rats. J Bone Miner Res. 1999;14:969-79. (Pubitemid 29262892)
69. Little DG, McDonald M, Bransford R, Godfrey CB, Amanat N. Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model. J Bone Miner Res. 2005;20:2044-52. (Pubitemid 41532790)
70. Amanat N, Brown R, Bilston LE, Little DG. A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair. J Orthop Res. 2005;23:1029-34. (Pubitemid 41245425)
71. Amanat N, McDonald M, Godfrey C, Bilston L, Little D. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res. 2007;22:867-76. (Pubitemid 351339747)
72. Durie BG. Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clin Proc. 2007;82:516-8.